Share
3,053 Posts.
lightbulb Created with Sketch. 2
clock Created with Sketch. 14/11/17
21:21
Share
Originally posted by kevg91
↑
......................................................................................UBS 11/05/2017 1 Buy $3.20 984.75% Quintis' one and only pharma customer has terminated its contract. Galderma acquired a competing acne brand back in March, leading the broker to question corporate governance given a long delay to disclosure. The termination also likely kills off any idea of a pharma spin-off. That leaves wood sales to China, where the risk is prices are not as healthy and the recent negative publicity the company has ensured has an impact. The broker nevertheless retains Buy and $3.20 target.
Expand
UBS suspended coverage of QIN in May after the galderma news dropped, that article is wrong. Jordan Rogers is still gainfully employed by UBS for some reason.
